Laffel LMB, et al. - A single-dose, open-label, randomized, parallel-group study was carried out to evaluate the pharmacokinetic and pharmacodynamic profile of a single dose of empagliflozin in young people with Type 2 diabetes as well as to identify the appropriate doses for further paediatric development. This study was conducted with empagliflozin 5 mg, 10 mg and 25 mg in young people with Type 2 diabetes aged 10–17 years. Researchers reported that after a single oral dose of empagliflozin, adults and young people with Type 2 diabetes had similar exposure-response associations after adjusting for significant covariates. In an upcoming paediatric phase III Type 2 diabetes trial, these data supported testing 10-mg and/or 25-mg doses of empagliflozin.